TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression

• Published in: Cell communication and signaling Vol. 22; no. 1; pp. 438 - 16
• Main Authors: Zhang, Bin-Bin, Zhao, Yi-Lin, Lu, Yan-Yu, Shen, Ji-Hong, Li, Hui-Yong, Zhang, Han-Xue, Yu, Xiao-Yue, Zhang, Wen-Cai, Li, Gang, Han, Zhan-Ying, Guo, Sen, Zhang, Xu-Tao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.09.2024; BioMed Central; BMC
• Subjects: Animals; Cardiac hypertrophy; Cardiomegaly - genetics; Cardiomegaly - metabolism; Cardiomegaly - pathology; Cardiomyocyte hypertrophy; Complications and side effects; Development and progression; Disease Progression; Health aspects; Heart enlargement; Humans; Male; MAP Kinase Kinase Kinases - genetics; MAP Kinase Kinase Kinases - metabolism; MAP Kinase Signaling System; Membrane proteins; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice; Mice, Inbred C57BL; Mitogen-activated protein kinases; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - pathology; Oxidative Stress; Phenylephrine - pharmacology; Physiological aspects; Protein–protein interaction; TAK1; TMEM100; China; TMEM100; Cardiac hypertrophy; Cardiomyocyte hypertrophy; TAK1; Protein–protein interaction
• ISSN: 1478-811X; 1478-811X
• DOI: 10.1186/s12964-024-01816-2

Pathological cardiac hypertrophy is the primary cause of heart failure, yet its underlying mechanisms remain incompletely understood. Transmembrane protein 100 (TMEM100) plays a role in various disorders, such as nervous system disease, pain and tumorigenesis, but its function in pathological cardiac hypertrophy is still unknown. In this study, we observed that TMEM100 is upregulated in cardiac hypertrophy. Functional investigations have shown that adeno-associated virus 9 (AAV9) mediated-TMEM100 overexpression mice attenuates transverse aortic constriction (TAC)-induced cardiac hypertrophy, including cardiomyocyte enlargement, cardiac fibrosis, and impaired heart structure and function. We subsequently demonstrated that adenoviral TMEM100 (AdTMEM100) mitigates phenylephrine (PE)-induced cardiomyocyte hypertrophy and downregulates the expression of cardiac hypertrophic markers in vitro, whereas TMEM100 knockdown exacerbates cardiomyocyte hypertrophy. The RNA sequences of the AdTMEM100 group and control group revealed that TMEM100 was involved in oxidative stress and the MAPK signaling pathway after PE stimulation. Mechanistically, we revealed that the transmembrane domain of TMEM100 (amino acids 53-75 and 85-107) directly interacts with the C-terminal region of TAK1 (amino acids 1-300) and inhibits the phosphorylation of TAK1 and its downstream molecules JNK and p38. TAK1-binding-defective TMEM100 failed to inhibit the activation of the TAK1-JNK/p38 pathway. Finally, the application of a TAK1 inhibitor (iTAK1) revealed that TAK1 is necessary for TMEM100-mediated cardiac hypertrophy. In summary, TMEM100 protects against pathological cardiac hypertrophy through the TAK1-JNK/p38 pathway and may serve as a promising target for the treatment of cardiac hypertrophy.